The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform


Argos in The News

Argos Therapeutics Reports Third Quarter 2015 Financial Results and Operational Highlights
Read more

Argos Therapeutics to Host Third Quarter 2015 Financial Results Conference Call on Monday, November 16, 2015
Read more

Argos Therapeutics to Participate in 3rd Annual EU Advanced Therapies Investor Day
Read more

> More News & Events >>>


When Our Company Was Founded


First Arcelis product (AGS-003) clinical trial initiated in mRCC


Phase 3 mRCC ADAPT Study Launched


Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC